Screening Protein Conformational Responses by Molecular Friction Sensing
This paper introduces Molecular Friction Sensing (MFS), a screening-compatible technique using DNA origami nanolevers to detect ligand-induced protein conformational changes with sub-Angström sensitivity, thereby adding a crucial structural dimension to drug discovery that reveals how binding affinity and kinetics alone cannot predict structural outcomes.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Proteins are the workhorses of life, tiny machines that build cells, send signals, and drive the chemistry of our bodies. For a long time, scientists pictured these molecules as static statues, frozen in a single, perfect shape. We now know this is not true. Proteins are flexible; they breathe, twist, and shift between different forms. This ability to change shape is often how they do their jobs. A drug might work not by blocking a protein like a key in a lock, but by nudging the protein into a specific shape that turns a function on or off. The challenge for researchers has been finding a way to see these subtle shape changes quickly. Traditional methods can tell us if a drug sticks to a protein, but they often cannot tell us if that drug actually changed the protein's shape. Without this information, it is difficult to know if a potential medicine will work the way scientists hope.
A team of researchers has developed a new way to watch these shape changes happen in real time. They created a method called molecular friction sensing, which acts like a highly sensitive scale for movement. Imagine a tiny, rigid arm made of DNA, anchored at one end to a surface. This arm is so small that it is invisible to the naked eye, but it is long enough to hold a single protein at its tip. The researchers apply a gentle electrical pulse to make this arm swing back and forth. When the arm swings, it pushes against the liquid around it, creating a kind of drag, or friction. If the protein attached to the tip is large or bulky, it creates more drag, and the arm swings more slowly. If the protein is small or compact, the arm swings faster. By measuring the speed of this swing with extreme precision, the researchers can determine the effective size of the protein.
The researchers tested this idea with a variety of proteins, ranging from very small ones to massive, complex structures. They found that the speed of the swinging arm changed in direct proportion to the size of the protein attached to it. This confirmed that the method could accurately measure the physical dimensions of a protein. But the real goal was to see if the method could detect when a protein changed its shape after grabbing a drug. To test this, they looked at a protein called maltodextrin-binding protein, which naturally interacts with sugar molecules. They introduced different types of sugar-like molecules to the protein. Some of these molecules were the ones the protein is designed to work with, while others were similar but not quite right. The researchers observed that when the correct sugar molecules bound to the protein, the protein changed its shape in a way that increased the friction, slowing the arm down. When the wrong molecules bound, the friction changed in a different way, or not at all. This showed that the method could distinguish between molecules that simply stuck to the protein and those that actually triggered a functional change in its shape.
To see if this approach could work as a tool for drug discovery, the team applied it to carbonic anhydrase, a common enzyme often used to test new drugs. They first identified twenty-two different compounds that were known to bind to this enzyme using standard methods. Then, they used molecular friction sensing to see how each of these compounds affected the enzyme's shape. The results were revealing. Some compounds that bound very tightly to the enzyme caused almost no change in its shape. Others, which might have been considered less effective by traditional measures, caused the enzyme to shift significantly. Crucially, the strength of the binding did not predict the shape change. A strong bond did not guarantee a big structural shift, and a weak bond did not mean the protein stayed the same. This means that knowing a drug sticks to a target is not enough to know what it will do to that target.
The study demonstrates that this new sensing technique can detect shape changes as small as a fraction of the width of a single atom. This level of sensitivity allows scientists to see the subtle differences between drugs that look similar on paper but act very differently inside the body. The researchers noted that the method works under normal biological conditions, using tiny amounts of protein, which makes it suitable for screening large libraries of potential medicines. By adding a measure of shape change to the standard tests for how well a drug binds, scientists can now prioritize candidates that are more likely to produce the desired biological effect. This approach offers a clearer path to understanding how drugs work, moving beyond simple binding to see the actual mechanical consequences of a molecule meeting its target.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.